Company
ASX:CHM
Chimeric Therapeutics Ltd, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. The company's world class team of cell therapy pioneers is focused on the discovery, development, and commercialisation of today's most innovative solutions, and has shown a consistent ability to deliver on its objectives.
83 stories · page 5 of 5
The company is developing CAR T cell therapies for solid tumours based on scientific research conducted by leading American CAR T experts at the City of Hope (COH) Cancer Centre in Los Angeles.
If the data is strong enough, the approval timeline may be accelerated due to the high unmet medical need in GBM.
The company is the only ASX-listed biotech conducting clinical trials in CAR-T technology and is focused on Phase 1 clinical trials for its CLTX-CAR T therapy for solid tumours.
